Researchers at the University of Chicago have shed light on the role of tumor-promoting factors induced by radiotherapy and their potential impact on future therapeutic strategies. The article, published in Nature on May 14, 2025, points to radiation-induced amphiregulin as a key driver of tumor metastasis.
With a PDUFA date less than four weeks away, Urogen Pharma Inc. has been having a rough ride on the Street since the U.S. FDA released a joint briefing document for the May 21 Oncologic Drugs Advisory Committee meeting on UGN-102 (mitomycin).
Newco Avidicure NV arrived on the scene with a hefty $50 million in seed funding to advance novel antibody formats the company says will surpass the best qualities of first-generation antibodies, checkpoint inhibitors, T-cell engagers and antibody-drug conjugates.
Korea Institute of Science and Technology has identified ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer.
Shanghai Yingli Pharmaceutical Co. Ltd. has synthesized poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Immune checkpoint inhibitors have revolutionized cancer therapy by reversing tumor-induced immunosuppression, but they fail to work for many patients because of resistance. In addition, they can reactivate immune pathways only from outside immune cells.
Metastatic castration-resistant prostate cancer (mCRPC) is driven by molecular and genetic alterations in multiple signaling pathways and usually progresses despite initial response to androgen deprivation therapy.
Prostate cancer, the second most frequent malignancy among men worldwide, can be treated using various antagonists of the androgen receptor, but many patients develop resistance within 18-24 months, and the resistance can block efficacy of not only the first-line antagonist but later-line antagonists as well. Therefore next-generation antagonists based on novel scaffolds are urgently needed.
RSS
